Slamon DJ, Neven P, Chia S, Jerusalem G, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone
receptor-positive, human epidermal growth factor receptor 2-negative advanced
breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall
survival. Ann Oncol 2021 May 15. pii: S0923-7534(21)01553.
PMID: 34102253